Indicator type;Execution Sectors;Total
Units carrying out R&D in Biotechnology;Total;1.575
Units carrying out R&D in Biotechnology;Public Administration;116
Units carrying out R&D in Biotechnology;Higher Education;68
Units carrying out R&D in Biotechnology;Companies;1.376
Units carrying out R&D in Biotechnology;NPPI;15
% Units by type of biotechnology used: Genetic Code;Total;38,4
% Units by type of biotechnology used: Genetic Code;Public Administration;90,5
% Units by type of biotechnology used: Genetic Code;Higher Education;91,2
% Units by type of biotechnology used: Genetic Code;Companies;31,4
% Units by type of biotechnology used: Genetic Code;NPPI;33,3
% Units by type of biotechnology used: Functional Units;Total;48,9
% Units by type of biotechnology used: Functional Units;Public Administration;86,2
% Units by type of biotechnology used: Functional Units;Higher Education;91,2
% Units by type of biotechnology used: Functional Units;Companies;43,7
% Units by type of biotechnology used: Functional Units;NPPI;40
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;Total;28,8
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;Public Administration;67,2
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;Higher Education;80,9
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;Companies;22,8
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;NPPI;46,7
% Units by type of biotechnology used: Bioprocesses;Total;50,9
% Units by type of biotechnology used: Bioprocesses;Public Administration;59,5
% Units by type of biotechnology used: Bioprocesses;Higher Education;92,7
% Units by type of biotechnology used: Bioprocesses;Companies;48,3
% Units by type of biotechnology used: Bioprocesses;NPPI;33,3
% Units by type of biotechnology used: Subcellular Organisms;Total;13,8
% Units by type of biotechnology used: Subcellular Organisms;Public Administration;50,9
% Units by type of biotechnology used: Subcellular Organisms;Higher Education;67,7
% Units by type of biotechnology used: Subcellular Organisms;Companies;7,9
% Units by type of biotechnology used: Subcellular Organisms;NPPI;26,7
% Units by type of biotechnology used: Bioinformatics;Total;33,1
% Units by type of biotechnology used: Bioinformatics;Public Administration;73,3
% Units by type of biotechnology used: Bioinformatics;Higher Education;85,3
% Units by type of biotechnology used: Bioinformatics;Companies;27,1
% Units by type of biotechnology used: Bioinformatics;NPPI;33,3
% Units by type of biotechnology used: Nanobiotechnology;Total;16,9
% Units by type of biotechnology used: Nanobiotechnology;Public Administration;50
% Units by type of biotechnology used: Nanobiotechnology;Higher Education;75
% Units by type of biotechnology used: Nanobiotechnology;Companies;11,2
% Units by type of biotechnology used: Nanobiotechnology;NPPI;13,3
% Units by type of biotechnology used: Other;Total;16,5
% Units by type of biotechnology used: Other;Public Administration;7,8
% Units by type of biotechnology used: Other;Higher Education;8,8
% Units by type of biotechnology used: Other;Companies;17,6
% Units by type of biotechnology used: Other;NPPI;20
Units in which biotechnology activities are: Main and/or exclusive;Total;752
Units in which biotechnology activities are: Main and/or exclusive;Public Administration;27
Units in which biotechnology activities are: Main and/or exclusive;Higher Education;6
Units in which biotechnology activities are: Main and/or exclusive;Companies;711
Units in which biotechnology activities are: Main and/or exclusive;NPPI;8
Units in which biotechnology activities are: A secondary business line;Total;354
Units in which biotechnology activities are: A secondary business line;Public Administration;39
Units in which biotechnology activities are: A secondary business line;Higher Education;42
Units in which biotechnology activities are: A secondary business line;Companies;270
Units in which biotechnology activities are: A secondary business line;NPPI;3
Units in which biotechnology activities are: A necessary tool for production;Total;469
Units in which biotechnology activities are: A necessary tool for production;Public Administration;50
Units in which biotechnology activities are: A necessary tool for production;Higher Education;20
Units in which biotechnology activities are: A necessary tool for production;Companies;395
Units in which biotechnology activities are: A necessary tool for production;NPPI;4
% Units by final application areas of biotechnology use: Human Health;Total;52,3
% Units by final application areas of biotechnology use: Human Health;Public Administration;78,5
% Units by final application areas of biotechnology use: Human Health;Higher Education;92,7
% Units by final application areas of biotechnology use: Human Health;Companies;48
% Units by final application areas of biotechnology use: Human Health;NPPI;60
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;Total;18,7
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;Public Administration;18,1
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;Higher Education;60,3
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;Companies;16,9
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;NPPI;6,7
% Units by final application areas of biotechnology use: Food Products;Total;31,1
% Units by final application areas of biotechnology use: Food Products;Public Administration;25
% Units by final application areas of biotechnology use: Food Products;Higher Education;80,9
% Units by final application areas of biotechnology use: Food Products;Companies;29,4
% Units by final application areas of biotechnology use: Food Products;NPPI;6,7
% Units by final application areas of biotechnology use: Agriculture and Forestry;Total;27,3
% Units by final application areas of biotechnology use: Agriculture and Forestry;Public Administration;22,4
% Units by final application areas of biotechnology use: Agriculture and Forestry;Higher Education;72,1
% Units by final application areas of biotechnology use: Agriculture and Forestry;Companies;25,7
% Units by final application areas of biotechnology use: Agriculture and Forestry;NPPI;13,3
% Units by final application areas of biotechnology use: Environment;Total;20,9
% Units by final application areas of biotechnology use: Environment;Public Administration;23,3
% Units by final application areas of biotechnology use: Environment;Higher Education;73,5
% Units by final application areas of biotechnology use: Environment;Companies;18
% Units by final application areas of biotechnology use: Environment;NPPI;26,7
% Units by final application areas of biotechnology use: Industry;Total;15,5
% Units by final application areas of biotechnology use: Industry;Public Administration;17,2
% Units by final application areas of biotechnology use: Industry;Higher Education;63,2
% Units by final application areas of biotechnology use: Industry;Companies;13
% Units by final application areas of biotechnology use: Industry;NPPI;6,7
R&D personnel in Biotechnology (PP);Total;49.624
R&D personnel in Biotechnology (PP);Public Administration;14.025
R&D personnel in Biotechnology (PP);Higher Education;18.065
R&D personnel in Biotechnology (PP);Companies;17.257
R&D personnel in Biotechnology (PP);NPPI;277
R&D personnel in Biotechnology (PP): Research personnel;Total;31.617
R&D personnel in Biotechnology (PP): Research personnel;Public Administration;8.400
R&D personnel in Biotechnology (PP): Research personnel;Higher Education;13.853
R&D personnel in Biotechnology (PP): Research personnel;Companies;9.195
R&D personnel in Biotechnology (PP): Research personnel;NPPI;169
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Total;18.006
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Public Administration;5.625
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Higher Education;4.212
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Companies;8.061
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;NPPI;108
R&D personnel in Biotechnology (PP). Women;Total;28.374
R&D personnel in Biotechnology (PP). Women;Public Administration;8.817
R&D personnel in Biotechnology (PP). Women;Higher Education;9.391
R&D personnel in Biotechnology (PP). Women;Companies;9.980
R&D personnel in Biotechnology (PP). Women;NPPI;186
R&D personnel in Biotechnology (PP). Women: Research personnel;Total;17.240
R&D personnel in Biotechnology (PP). Women: Research personnel;Public Administration;4.979
R&D personnel in Biotechnology (PP). Women: Research personnel;Higher Education;6.935
R&D personnel in Biotechnology (PP). Women: Research personnel;Companies;5.222
R&D personnel in Biotechnology (PP). Women: Research personnel;NPPI;104
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Total;11.134
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Public Administration;3.838
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Higher Education;2.456
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Companies;4.758
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;NPPI;82
R&D personnel in Biotechnology (FTE);Total;35.793,8
R&D personnel in Biotechnology (FTE);Public Administration;10.811,1
R&D personnel in Biotechnology (FTE);Higher Education;11.886,5
R&D personnel in Biotechnology (FTE);Companies;12.883,4
R&D personnel in Biotechnology (FTE);NPPI;212,8
R&D personnel in Biotechnology (FTE): Research personnel;Total;22.776
R&D personnel in Biotechnology (FTE): Research personnel;Public Administration;6.354,5
R&D personnel in Biotechnology (FTE): Research personnel;Higher Education;9.188,3
R&D personnel in Biotechnology (FTE): Research personnel;Companies;7.103,2
R&D personnel in Biotechnology (FTE): Research personnel;NPPI;130
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Total;13.017,8
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Public Administration;4.456,6
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Higher Education;2.698,2
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Companies;5.780,2
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;NPPI;82,8
R&D personnel in Biotechnology (FTE). Women;Total;20.951,5
R&D personnel in Biotechnology (FTE). Women;Public Administration;6.766,8
R&D personnel in Biotechnology (FTE). Women;Higher Education;6.436,5
R&D personnel in Biotechnology (FTE). Women;Companies;7.600,6
R&D personnel in Biotechnology (FTE). Women;NPPI;147,6
R&D personnel in Biotechnology (FTE). Women: Research personnel;Total;12.634,4
R&D personnel in Biotechnology (FTE). Women: Research personnel;Public Administration;3.729,2
R&D personnel in Biotechnology (FTE). Women: Research personnel;Higher Education;4.765
R&D personnel in Biotechnology (FTE). Women: Research personnel;Companies;4.057
R&D personnel in Biotechnology (FTE). Women: Research personnel;NPPI;83,2
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Total;8.317,2
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Public Administration;3.037,6
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Higher Education;1.671,5
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Companies;3.543,7
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;NPPI;64,4
Expenditure on internal R&D in Biotechnology (thousands of euros);Total;2.748.629
Expenditure on internal R&D in Biotechnology (thousands of euros);Public Administration;790.000
Expenditure on internal R&D in Biotechnology (thousands of euros);Higher Education;663.966
Expenditure on internal R&D in Biotechnology (thousands of euros);Companies;1.283.346
Expenditure on internal R&D in Biotechnology (thousands of euros);NPPI;11.317
1) By type of expenditure: Current expenditure;Total;2.534.791
1) By type of expenditure: Current expenditure;Public Administration;737.638
1) By type of expenditure: Current expenditure;Higher Education;606.138
1) By type of expenditure: Current expenditure;Companies;1.180.187
1) By type of expenditure: Current expenditure;NPPI;10.827
1.1) Labour expenditure of research personnel;Total;1.028.782
1.1) Labour expenditure of research personnel;Public Administration;268.921
1.1) Labour expenditure of research personnel;Higher Education;383.808
1.1) Labour expenditure of research personnel;Companies;372.421
1.1) Labour expenditure of research personnel;NPPI;3.632
1.2) Labour expenditure of technical and auxiliary personnel;Total;479.176
1.2) Labour expenditure of technical and auxiliary personnel;Public Administration;155.370
1.2) Labour expenditure of technical and auxiliary personnel;Higher Education;91.894
1.2) Labour expenditure of technical and auxiliary personnel;Companies;229.734
1.2) Labour expenditure of technical and auxiliary personnel;NPPI;2.178
1.3) Other current expenditure;Total;1.026.833
1.3) Other current expenditure;Public Administration;313.348
1.3) Other current expenditure;Higher Education;130.437
1.3) Other current expenditure;Companies;578.032
1.3) Other current expenditure;NPPI;5.017
2) By type of expenditure: Capital expenditure;Total;213.838
2) By type of expenditure: Capital expenditure;Public Administration;52.362
2) By type of expenditure: Capital expenditure;Higher Education;57.827
2) By type of expenditure: Capital expenditure;Companies;103.159
2) By type of expenditure: Capital expenditure;NPPI;490
2.1) Land and buildings;Total;28.577
2.1) Land and buildings;Public Administration;5.863
2.1) Land and buildings;Higher Education;11.615
2.1) Land and buildings;Companies;10.889
2.1) Land and buildings;NPPI;210
2.2) Equipment and tools;Total;146.829
2.2) Equipment and tools;Public Administration;45.051
2.2) Equipment and tools;Higher Education;42.322
2.2) Equipment and tools;Companies;59.204
2.2) Equipment and tools;NPPI;253
2.3) Acquisition of specific R&D software;Total;7.338
2.3) Acquisition of specific R&D software;Public Administration;1.354
2.3) Acquisition of specific R&D software;Higher Education;339
2.3) Acquisition of specific R&D software;Companies;5.623
2.3) Acquisition of specific R&D software;NPPI;21
2.4) Other R&D-specific IP products;Total;31.094
2.4) Other R&D-specific IP products;Public Administration;94
2.4) Other R&D-specific IP products;Higher Education;3.552
2.4) Other R&D-specific IP products;Companies;27.442
2.4) Other R&D-specific IP products;NPPI;6
1.1) By origin of funds: Own funds;Total;1.107.216
1.1) By origin of funds: Own funds;Public Administration;99.226
1.1) By origin of funds: Own funds;Higher Education;117.157
1.1) By origin of funds: Own funds;Companies;887.527
1.1) By origin of funds: Own funds;NPPI;3.306
1.2) By origin of funds: Funds from the Business sector;Total;258.957
1.2) By origin of funds: Funds from the Business sector;Public Administration;69.960
1.2) By origin of funds: Funds from the Business sector;Higher Education;42.038
1.2) By origin of funds: Funds from the Business sector;Companies;143.903
1.2) By origin of funds: Funds from the Business sector;NPPI;3.055
1.3) By origin of funds: Funds from the Public Administration sector;Total;1.065.003
1.3) By origin of funds: Funds from the Public Administration sector;Public Administration;512.667
1.3) By origin of funds: Funds from the Public Administration sector;Higher Education;424.208
1.3) By origin of funds: Funds from the Public Administration sector;Companies;126.546
1.3) By origin of funds: Funds from the Public Administration sector;NPPI;1.582
1.4) By origin of funds: Funds from the Higher Education sector;Total;5.113
1.4) By origin of funds: Funds from the Higher Education sector;Public Administration;1.150
1.4) By origin of funds: Funds from the Higher Education sector;Higher Education;3.842
1.4) By origin of funds: Funds from the Higher Education sector;Companies;94
1.4) By origin of funds: Funds from the Higher Education sector;NPPI;27
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Total;51.237
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Public Administration;20.158
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Higher Education;17.468
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Companies;12.623
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;NPPI;988
1.6) By origin of funds: Funds from the rest of the world;Total;261.103
1.6) By origin of funds: Funds from the rest of the world;Public Administration;86.839
1.6) By origin of funds: Funds from the rest of the world;Higher Education;59.252
1.6) By origin of funds: Funds from the rest of the world;Companies;112.652
1.6) By origin of funds: Funds from the rest of the world;NPPI;2.359
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Total;177.658
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Public Administration;38.288
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Higher Education;1.802
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Companies;137.432
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);NPPI;135
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Total;124.133
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Public Administration;34.179
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Higher Education;1.692
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Companies;88.127
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;NPPI;134
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Total;53.525
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Public Administration;4.109
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Higher Education;110
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Companies;49.305
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;NPPI;1
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Total;45,9
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Public Administration;65,5
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Higher Education;50
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Companies;43,7
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;NPPI;73,3
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Total;15,5
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Public Administration;10,3
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Higher Education;11,8
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Companies;16,2
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;NPPI;6,7
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Total;25,8
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Public Administration;47,4
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Higher Education;33,8
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Companies;23,7
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;NPPI;20
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Total;15,7
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Public Administration;21,6
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Higher Education;33,8
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Companies;14,5
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;NPPI;6,7
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Total;20,1
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Public Administration;27,6
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Higher Education;44,1
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Companies;18,1
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;NPPI;40
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Total;21,1
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Public Administration;29,3
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Higher Education;41,2
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Companies;19,6
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;NPPI;6,7
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Total;17,9
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Public Administration;7,8
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Higher Education;10,3
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Companies;19,1
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;NPPI;13,3
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Total;49,3
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Public Administration;47,4
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Higher Education;44,1
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Companies;49,8
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;NPPI;33,3
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Total;59,5
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Public Administration;59,5
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Higher Education;60,3
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Companies;59,4
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;NPPI;73,3
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Total;22,1
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Public Administration;20,7
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Higher Education;17,6
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Companies;22,3
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;NPPI;33,3